Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer.

@article{Chen2012PhaseIS,
  title={Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer.},
  author={Ronald C. Chen and Julian G. Rosenman and Leroy G Hoffman and W Chiu and Andrew Z. Wang and Raj Som Pruthi and Eric. M. Wallen and Jeffrey M Crane and William Y. Kim and W. Kimryn Rathmell and Paul Alphonso Godley and Young E. Whang},
  journal={BJU international},
  year={2012},
  volume={110 11 Pt B},
  pages={E721-6}
}
UNLABELLED Study Type - Therapy (phase 1) Level of Evidence 2a What's known on the subject? and What does the study add? High-risk and locally advanced prostate cancers are difficult to cure with the standard regimen of radiation therapy (RT) with concurrent androgen-deprivation therapy (ADT). Multiple studies have explored the addition of docetaxel chemotherapy in attempt to improve patient outcomes. Prior Phase I studies have shown that docetaxel 20 mg/m(2) is a safe dose, when given… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 24 references

Cancer statistics ,

  • R Siegel, E Ward, O Brawley, A Jemal
  • 2011

Long - term results after high - dose radiotherapy and adjuvant hormones in prostate cancer : how curable is high - risk disease ?

  • IF Tannock, R deWit, WR Berry
  • Int J Radiat Oncol Biol Phys
  • 2011

Similar Papers

Loading similar papers…